1380424-42-9

Basic information

• Product Name: KML-29
• Synonyms: KML-29
• CAS NO: 1380424-42-9
• Molecular Formula: C24H21F6NO7
• Molecular Weight: 549.4164592
• Product Categories: Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;Heterocycles, Inhibitors, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 1380424-42-9.mol

Chemical Properties

• Boiling Point: 554.8±50.0 °C(Predicted)
• Appearance: /
• Density: 1.511±0.06 g/cm3(Predicted)
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly, Heated, Sonicated), Methanol (Slightly, Heated)
• PKA: 13.32±0.29(Predicted)
• CAS DataBase Reference: KML-29(CAS DataBase Reference)
• NIST Chemistry Reference: KML-29(1380424-42-9)
• EPA Substance Registry System: KML-29(1380424-42-9)

Safety Data

• Hazardous Substances Data: 1380424-42-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
KML-29 is used as a research tool for studying the role of endocannabinoids in synaptic processes and their interactions with cannabinoid receptors. Its ability to inhibit MAGL selectively allows researchers to distinguish between the actions of 2-AG and anandamide, another endocannabinoid.
Used in Drug Development:
KML-29 is used as a starting point for the development of new drugs targeting the endocannabinoid system. Its potent and selective inhibition of MAGL can potentially lead to the creation of therapeutic agents for various conditions related to the dysregulation of the endocannabinoid system.
Used in Neurological Applications:
KML-29 is used as a therapeutic agent for neurological disorders that involve the endocannabinoid system, such as chronic pain, anxiety, and neurodegenerative diseases. By inhibiting MAGL, KML-29 can modulate the levels of endocannabinoids, potentially leading to improved treatment outcomes for these conditions.
Used in Preclinical Studies:
KML-29 is used in preclinical studies to evaluate its efficacy and safety as a potential therapeutic agent. These studies involve testing KML-29 in animal models to determine its pharmacokinetics, pharmacodynamics, and potential side effects before moving on to clinical trials in humans.

Upstream product

• 32315-10-9 bis(trichloromethyl) carbonate 
• 920-66-1 1,1,1,3',3',3'-hexafluoro-propanol 
• 1446818-43-4 4-(bis(3,4-dioxymethylenephenyl)hydroxymethyl)piperidine 
• 1446818-42-3 tert-butyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)-piperidine-1-carboxylate 
• 2635-13-4 1,2-(methylenedioxy)-4-bromobenzene 
• 142851-03-4 1-tert-butyl 4-ethyl piperidine-1,4-dicarboxylate 

Relevant articles and documents

CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME

This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compunds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from indications such as pain, solid tumor cancer and/or obesity comprising administering a disclosed compound or composition.